Abstract
Summary
LPI (LP Information)' newest research report, the “Cancer Generics Industry Forecast” looks at past sales and reviews total world Cancer Generics sales in 2022, providing a comprehensive analysis by region and market sector of projected Cancer Generics sales for 2023 through 2029. With Cancer Generics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Generics industry.
This Insight Report provides a comprehensive analysis of the global Cancer Generics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Generics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Generics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Generics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Generics.
The global Cancer Generics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cancer Generics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cancer Generics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cancer Generics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cancer Generics players cover Teva Pharmaceuticals, Pfizer, Accord Healthcare, Amneal Pharmaceuticals, Mylan, DrReddy Laboratories, Bedford Pharma, Hikma and Cipla, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Generics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Chemotherapy
Biological Targeted Therapy Drugs
Prescription Drugs
Chinese Patent Medicine
Other
Segmentation by application
Hospital
Clinic
Drug Center
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva Pharmaceuticals
Pfizer
Accord Healthcare
Amneal Pharmaceuticals
Mylan
DrReddy Laboratories
Bedford Pharma
Hikma
Cipla
Shilpa Medicare
Fresenius Kabi
Zydus Pharmaceuticals
Neopharm
Netco
Mayne Pharma
Alvogen
Glenmark
HBT Labs
Gland
Qilu Pharmaceuticals
Akorn Pharmaceuticals
MSN Group
Wockhardt
Rising Pharma
Apotex
Taro Pharmaceuticals
Sun Pharma
Alkem Laboratories
Endo Pharma
This Insight Report provides a comprehensive analysis of the global Cancer Generics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Generics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Cancer Generics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Generics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Generics.
The global Cancer Generics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cancer Generics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cancer Generics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cancer Generics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cancer Generics players cover Teva Pharmaceuticals, Pfizer, Accord Healthcare, Amneal Pharmaceuticals, Mylan, DrReddy Laboratories, Bedford Pharma, Hikma and Cipla, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Generics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Chemotherapy
Biological Targeted Therapy Drugs
Prescription Drugs
Chinese Patent Medicine
Other
Segmentation by application
Hospital
Clinic
Drug Center
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Teva Pharmaceuticals
Pfizer
Accord Healthcare
Amneal Pharmaceuticals
Mylan
DrReddy Laboratories
Bedford Pharma
Hikma
Cipla
Shilpa Medicare
Fresenius Kabi
Zydus Pharmaceuticals
Neopharm
Netco
Mayne Pharma
Alvogen
Glenmark
HBT Labs
Gland
Qilu Pharmaceuticals
Akorn Pharmaceuticals
MSN Group
Wockhardt
Rising Pharma
Apotex
Taro Pharmaceuticals
Sun Pharma
Alkem Laboratories
Endo Pharma
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cancer Generics Market Size 2018-2029
2.1.2 Cancer Generics Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Cancer Generics Segment by Type
2.2.1 Chemotherapy
2.2.2 Biological Targeted Therapy Drugs
2.2.3 Prescription Drugs
2.2.4 Chinese Patent Medicine
2.2.5 Other
2.3 Cancer Generics Market Size by Type
2.3.1 Cancer Generics Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Cancer Generics Market Size Market Share by Type (2018-2023)
2.4 Cancer Generics Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Drug Center
2.4.4 Other
2.5 Cancer Generics Market Size by Application
2.5.1 Cancer Generics Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Cancer Generics Market Size Market Share by Application (2018-2023)
3 Cancer Generics Market Size by Player
3.1 Cancer Generics Market Size Market Share by Players
3.1.1 Global Cancer Generics Revenue by Players (2018-2023)
3.1.2 Global Cancer Generics Revenue Market Share by Players (2018-2023)
3.2 Global Cancer Generics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Cancer Generics by Regions
4.1 Cancer Generics Market Size by Regions (2018-2023)
4.2 Americas Cancer Generics Market Size Growth (2018-2023)
4.3 APAC Cancer Generics Market Size Growth (2018-2023)
4.4 Europe Cancer Generics Market Size Growth (2018-2023)
4.5 Middle East & Africa Cancer Generics Market Size Growth (2018-2023)
5 Americas
5.1 Americas Cancer Generics Market Size by Country (2018-2023)
5.2 Americas Cancer Generics Market Size by Type (2018-2023)
5.3 Americas Cancer Generics Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Cancer Generics Market Size by Region (2018-2023)
6.2 APAC Cancer Generics Market Size by Type (2018-2023)
6.3 APAC Cancer Generics Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Cancer Generics by Country (2018-2023)
7.2 Europe Cancer Generics Market Size by Type (2018-2023)
7.3 Europe Cancer Generics Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Cancer Generics by Region (2018-2023)
8.2 Middle East & Africa Cancer Generics Market Size by Type (2018-2023)
8.3 Middle East & Africa Cancer Generics Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Cancer Generics Market Forecast
10.1 Global Cancer Generics Forecast by Regions (2024-2029)
10.1.1 Global Cancer Generics Forecast by Regions (2024-2029)
10.1.2 Americas Cancer Generics Forecast
10.1.3 APAC Cancer Generics Forecast
10.1.4 Europe Cancer Generics Forecast
10.1.5 Middle East & Africa Cancer Generics Forecast
10.2 Americas Cancer Generics Forecast by Country (2024-2029)
10.2.1 United States Cancer Generics Market Forecast
10.2.2 Canada Cancer Generics Market Forecast
10.2.3 Mexico Cancer Generics Market Forecast
10.2.4 Brazil Cancer Generics Market Forecast
10.3 APAC Cancer Generics Forecast by Region (2024-2029)
10.3.1 China Cancer Generics Market Forecast
10.3.2 Japan Cancer Generics Market Forecast
10.3.3 Korea Cancer Generics Market Forecast
10.3.4 Southeast Asia Cancer Generics Market Forecast
10.3.5 India Cancer Generics Market Forecast
10.3.6 Australia Cancer Generics Market Forecast
10.4 Europe Cancer Generics Forecast by Country (2024-2029)
10.4.1 Germany Cancer Generics Market Forecast
10.4.2 France Cancer Generics Market Forecast
10.4.3 UK Cancer Generics Market Forecast
10.4.4 Italy Cancer Generics Market Forecast
10.4.5 Russia Cancer Generics Market Forecast
10.5 Middle East & Africa Cancer Generics Forecast by Region (2024-2029)
10.5.1 Egypt Cancer Generics Market Forecast
10.5.2 South Africa Cancer Generics Market Forecast
10.5.3 Israel Cancer Generics Market Forecast
10.5.4 Turkey Cancer Generics Market Forecast
10.5.5 GCC Countries Cancer Generics Market Forecast
10.6 Global Cancer Generics Forecast by Type (2024-2029)
10.7 Global Cancer Generics Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Teva Pharmaceuticals
11.1.1 Teva Pharmaceuticals Company Information
11.1.2 Teva Pharmaceuticals Cancer Generics Product Offered
11.1.3 Teva Pharmaceuticals Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Teva Pharmaceuticals Main Business Overview
11.1.5 Teva Pharmaceuticals Latest Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Cancer Generics Product Offered
11.2.3 Pfizer Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Pfizer Main Business Overview
11.2.5 Pfizer Latest Developments
11.3 Accord Healthcare
11.3.1 Accord Healthcare Company Information
11.3.2 Accord Healthcare Cancer Generics Product Offered
11.3.3 Accord Healthcare Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Accord Healthcare Main Business Overview
11.3.5 Accord Healthcare Latest Developments
11.4 Amneal Pharmaceuticals
11.4.1 Amneal Pharmaceuticals Company Information
11.4.2 Amneal Pharmaceuticals Cancer Generics Product Offered
11.4.3 Amneal Pharmaceuticals Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Amneal Pharmaceuticals Main Business Overview
11.4.5 Amneal Pharmaceuticals Latest Developments
11.5 Mylan
11.5.1 Mylan Company Information
11.5.2 Mylan Cancer Generics Product Offered
11.5.3 Mylan Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Mylan Main Business Overview
11.5.5 Mylan Latest Developments
11.6 DrReddy Laboratories
11.6.1 DrReddy Laboratories Company Information
11.6.2 DrReddy Laboratories Cancer Generics Product Offered
11.6.3 DrReddy Laboratories Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 DrReddy Laboratories Main Business Overview
11.6.5 DrReddy Laboratories Latest Developments
11.7 Bedford Pharma
11.7.1 Bedford Pharma Company Information
11.7.2 Bedford Pharma Cancer Generics Product Offered
11.7.3 Bedford Pharma Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Bedford Pharma Main Business Overview
11.7.5 Bedford Pharma Latest Developments
11.8 Hikma
11.8.1 Hikma Company Information
11.8.2 Hikma Cancer Generics Product Offered
11.8.3 Hikma Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Hikma Main Business Overview
11.8.5 Hikma Latest Developments
11.9 Cipla
11.9.1 Cipla Company Information
11.9.2 Cipla Cancer Generics Product Offered
11.9.3 Cipla Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Cipla Main Business Overview
11.9.5 Cipla Latest Developments
11.10 Shilpa Medicare
11.10.1 Shilpa Medicare Company Information
11.10.2 Shilpa Medicare Cancer Generics Product Offered
11.10.3 Shilpa Medicare Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Shilpa Medicare Main Business Overview
11.10.5 Shilpa Medicare Latest Developments
11.11 Fresenius Kabi
11.11.1 Fresenius Kabi Company Information
11.11.2 Fresenius Kabi Cancer Generics Product Offered
11.11.3 Fresenius Kabi Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Fresenius Kabi Main Business Overview
11.11.5 Fresenius Kabi Latest Developments
11.12 Zydus Pharmaceuticals
11.12.1 Zydus Pharmaceuticals Company Information
11.12.2 Zydus Pharmaceuticals Cancer Generics Product Offered
11.12.3 Zydus Pharmaceuticals Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Zydus Pharmaceuticals Main Business Overview
11.12.5 Zydus Pharmaceuticals Latest Developments
11.13 Neopharm
11.13.1 Neopharm Company Information
11.13.2 Neopharm Cancer Generics Product Offered
11.13.3 Neopharm Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Neopharm Main Business Overview
11.13.5 Neopharm Latest Developments
11.14 Netco
11.14.1 Netco Company Information
11.14.2 Netco Cancer Generics Product Offered
11.14.3 Netco Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Netco Main Business Overview
11.14.5 Netco Latest Developments
11.15 Mayne Pharma
11.15.1 Mayne Pharma Company Information
11.15.2 Mayne Pharma Cancer Generics Product Offered
11.15.3 Mayne Pharma Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Mayne Pharma Main Business Overview
11.15.5 Mayne Pharma Latest Developments
11.16 Alvogen
11.16.1 Alvogen Company Information
11.16.2 Alvogen Cancer Generics Product Offered
11.16.3 Alvogen Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Alvogen Main Business Overview
11.16.5 Alvogen Latest Developments
11.17 Glenmark
11.17.1 Glenmark Company Information
11.17.2 Glenmark Cancer Generics Product Offered
11.17.3 Glenmark Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Glenmark Main Business Overview
11.17.5 Glenmark Latest Developments
11.18 HBT Labs
11.18.1 HBT Labs Company Information
11.18.2 HBT Labs Cancer Generics Product Offered
11.18.3 HBT Labs Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 HBT Labs Main Business Overview
11.18.5 HBT Labs Latest Developments
11.19 Gland
11.19.1 Gland Company Information
11.19.2 Gland Cancer Generics Product Offered
11.19.3 Gland Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.19.4 Gland Main Business Overview
11.19.5 Gland Latest Developments
11.20 Qilu Pharmaceuticals
11.20.1 Qilu Pharmaceuticals Company Information
11.20.2 Qilu Pharmaceuticals Cancer Generics Product Offered
11.20.3 Qilu Pharmaceuticals Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.20.4 Qilu Pharmaceuticals Main Business Overview
11.20.5 Qilu Pharmaceuticals Latest Developments
11.21 Akorn Pharmaceuticals
11.21.1 Akorn Pharmaceuticals Company Information
11.21.2 Akorn Pharmaceuticals Cancer Generics Product Offered
11.21.3 Akorn Pharmaceuticals Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.21.4 Akorn Pharmaceuticals Main Business Overview
11.21.5 Akorn Pharmaceuticals Latest Developments
11.22 MSN Group
11.22.1 MSN Group Company Information
11.22.2 MSN Group Cancer Generics Product Offered
11.22.3 MSN Group Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.22.4 MSN Group Main Business Overview
11.22.5 MSN Group Latest Developments
11.23 Wockhardt
11.23.1 Wockhardt Company Information
11.23.2 Wockhardt Cancer Generics Product Offered
11.23.3 Wockhardt Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.23.4 Wockhardt Main Business Overview
11.23.5 Wockhardt Latest Developments
11.24 Rising Pharma
11.24.1 Rising Pharma Company Information
11.24.2 Rising Pharma Cancer Generics Product Offered
11.24.3 Rising Pharma Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.24.4 Rising Pharma Main Business Overview
11.24.5 Rising Pharma Latest Developments
11.25 Apotex
11.25.1 Apotex Company Information
11.25.2 Apotex Cancer Generics Product Offered
11.25.3 Apotex Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.25.4 Apotex Main Business Overview
11.25.5 Apotex Latest Developments
11.26 Taro Pharmaceuticals
11.26.1 Taro Pharmaceuticals Company Information
11.26.2 Taro Pharmaceuticals Cancer Generics Product Offered
11.26.3 Taro Pharmaceuticals Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.26.4 Taro Pharmaceuticals Main Business Overview
11.26.5 Taro Pharmaceuticals Latest Developments
11.27 Sun Pharma
11.27.1 Sun Pharma Company Information
11.27.2 Sun Pharma Cancer Generics Product Offered
11.27.3 Sun Pharma Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.27.4 Sun Pharma Main Business Overview
11.27.5 Sun Pharma Latest Developments
11.28 Alkem Laboratories
11.28.1 Alkem Laboratories Company Information
11.28.2 Alkem Laboratories Cancer Generics Product Offered
11.28.3 Alkem Laboratories Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.28.4 Alkem Laboratories Main Business Overview
11.28.5 Alkem Laboratories Latest Developments
11.29 Endo Pharma
11.29.1 Endo Pharma Company Information
11.29.2 Endo Pharma Cancer Generics Product Offered
11.29.3 Endo Pharma Cancer Generics Revenue, Gross Margin and Market Share (2018-2023)
11.29.4 Endo Pharma Main Business Overview
11.29.5 Endo Pharma Latest Developments
12 Research Findings and Conclusion